Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cue Biopharma, Inc.

https://www.cuebiopharma.com/

Latest From Cue Biopharma, Inc.

Scrip Asks…What Does 2022 Hold For Biopharma? Part 4: Therapeutic Area Advances

Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.

Scrip Asks Coronavirus COVID-19

Tech Transfer Roundup: Inside The Law That Transformed The Research Landscape

The Bayh-Dole act of 1980 facilitated deal-making between private-sector firms and research institutions, largely seeding the US biotech industry. Plus, an overview of the latest tech transfer deals.

Deals Business Strategies

NIH, BARDA Seek Out New Point-Of-Care Diagnostics For RADx Program To Boost US COVID-19 Testing

The US National Institutes of Health and the Biomedical Advanced Research and Development Authority are asking manufacturers to provide new COVID-19 diagnostic candidates for NIH’s Rapid Acceleration of Diagnostics (RADx) program.

Policy Coronavirus COVID-19

Scrip Asks…What Does 2020 Hold For Biopharma? Part 1: Therapeutic Advances

Advances in multiple scientific areas will mature into novel therapeutics, often tailored for the individual patient and increasingly curative, making biopharma an exciting place to be in 2020.

Innovation Scrip Asks
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
UsernamePublicRestriction

Register